Paraganglioma Treatment Market With Leading Players are AstraZeneca, Advanced Accelerator Applications, Jubilant Life Sciences Ltd, Pfizer

The Paraganglioma Treatment report identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the market. This Paraganglioma Treatment market report performs comprehensive analysis of profiles of key market players that gives a competitive landscape to the businesses. Besides this, market drivers, market restraints, opportunities and challenges are evaluated under market overview which gives valuable insights to businesses for taking right moves. The report comprises of precise and up to date information about the consumer’s demands, their preferences, and their variable likings about particular product. No stone is left unturned about the market research analysis while generating and presenting this Paraganglioma Treatment market research report to the clients which satisfies their anticipation.

Global Paraganglioma Treatment Market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Presence of refined healthcare infrastructure and increase in special designation from the regulatory authorities are the key factors that drive the market

Paraganglioma is also known as pheochromocytoma is ultra-rare neuroendocrine cancers that arise from cells called paraganglia. Paraganglia cells are found near nerve cell bunches called ganglia. Most paraganglioma originate in one of the two adrenal glands located above the kidneys in the back of the upper abdomen. It causes over activation of adrenal hormones that can lead to life-threatening high blood pressure, heart failure, and stroke in these patients.

According to the statistics published in the U.S. Department of Health & Human Services, an estimated annual prevalence of paragangliomas is 1 in every 1 million people worldwide. Introduction of the drugs used to treat complication associated with paragangliomas and presence of refined healthcare infrastructure is fueling the growth of this market.

Request for Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-paraganglioma-treatment-market

Market Drivers

Increase in special designation from the regulatory authorities is drive the market
Growing prevalence of cancer has boosted the development of the novel treatments can enhance the market growth
Rise in number of patients suffering from paragangliomas and continuous advances in the treatment is propelling the market growth
Huge financial support to the researchers for developing novel intervention is boosting the market growth
Segmentation: Global Paraganglioma Treatment Market

By Type

Sympathetic Paragangliomas
Parasympathetic Paragangliomas
By Site of Origin

Caroid Paragangliomas
Cervical Paragangliomas
Vagal Paragangliomas
Others
By Therapy Type

Radiation Therapy
Chemotherapy
Peptide Receptor Radionuclide Therapy (PRRT)
Others
By Treatment

Medication
Surgery
By Drugs

Iobenguane I 131
Cyclophosphamide
Vincristine
Dacarbazine
Others
By Route of Administration

Oral
Injectable
By End Users

Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others
By Geography

North America
South America
Europe
Asia-Pacific
Middle East & Africa
Browse Full Report with Details TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-paraganglioma-treatment-market

Key Developments in the Market:

In August 2018, Progenics Pharmaceuticals, Inc received approval from the FDA for Azedra (iobenguane I131), a radioactive therapeutic agent for the treatment of locally advanced or metastatic pheochromocytoma or paraganglioma in adult and pediatric patients 12 years and older. This drug has also received Breakthrough Therapy designation, an Orphan Drug designation, Fast Track designations and Priority Review from the FDA for the treatment of iobenguane-avid metastatic paraganglioma and pheochromocytoma. The approval of Azedra represents major advances in non-surgical treatment for ultra-rare cancer paraganglioma.
In August 2016, Advanced Accelerator Applications entered into research collaboration with National Cancer Institute to develop Lutathera, a Lu-177-labeled somatostatin analogue peptide for the treatment of pheochromocytoma and paraganglioma. Under the terms of deal, National Cancer Institute will have the responsibility to conduct clinical trial studies. This collaboration will provide the funds and assist the development of new class of therapeutics to treat patients suffering from paraganglioma.
Inquiry before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-paraganglioma-treatment-market

Competitive Analysis:

Global paraganglioma treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global paraganglioma treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global paraganglioma treatment market are Progenics Pharmaceuticals, Inc, AstraZeneca, Advanced Accelerator Applications, Jubilant Life Sciences Ltd, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Cipla Inc, Amneal Pharmaceuticals LLC, Amerigen Pharmaceuticals Limited, Jiangsu Hengrui Medicine Co., Ltd, Fresenius Kabi AG, ONO PHARMACEUTICAL CO., LTD and others.

Research Methodology: Global Paraganglioma Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

This release was published on openPR.